BeOne Medicines Expands BRUKINSA Access for CLL Patients
SAN CARLOS, Calif. & SEATTLE, Aug. 18, 2026 BeOne Medicines Ltd., together with the BeOne Care Foundation and The...
Zanubrutinib
Advertisement
Curis Advances TakeAim CLL Trial with First Patients Dosed
LEXINGTON, Mass., July 30, 2026 Curis, Inc. has reached an important clinical milestone by successfully dosing the first five...
Curis Achieves Early Enrollment in Phase 2 CLL Trial
LEXINGTON, Mass., July 6, 2026 Curis, Inc. announced an important enrollment milestone for its Phase 2 TakeAim CLL clinical...
Curis Reaffirms Initial Patient Dosing Timeline for TakeAim CLL Trial
LEXINGTON, Mass., June 26, 2026 Curis, Inc. announced continued progress in its Phase 2 TakeAim CLL clinical trial, confirming...
BeOne Sets New CLL Benchmark with 78-Month BRUKINSA Data at ASCO 2026
SAN CARLOS, Calif. | May 29, 2026 BeOne Medicines presented groundbreaking long-term data at the 2026 American Society of...
Advertisement
